prnewswire.com
Neutralwww.prnewswire.com ·
Antengene Receives Cde Endorsement to Initiate Pivotal Phase Iii Clinch 3 Study of Atg 022 in Cldn18 2 Advanced Gastricgej Cancer
MyelomaBladder CancerInvestorMedical
Topic context
This topic has been covered 294780 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedAntengene (HKEX listed) advances ATG-022 to pivotal Phase III in China. Commercial mechanism is weak: regulatory endorsement enables a clinical trial, not a market launch. No revenue, pricing, or supply chain impact until approval. Sector PHARMA_BIOTECH is relevant as a drug developer, but no concrete commercial signal yet.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Antengene received CDE endorsement for Phase III CLINCH-3 study of ATG-022 in CLDN18.2+ advanced gastric/GEJ adenocarcinoma.
- Study is led by Prof. Lin Shen from Peking University Cancer Hospital.
- Primary endpoints: progression-free survival and overall survival.
- ATG-022 is an antibody-drug conjugate targeting CLDN18.2.
- Study follows promising earlier trial results.
Related stories
forbes.com
Forbes 30 Under 30 Asia the Social Entrepreneurs Tackling Issues From Food Waste to Inequality
wral.com
Greg Lindberg Sentenced Prison Nc Money Laundering Insurance Political Donor May 2026
larouchepub.com
5321 humanity s future must be deci
malaysiasun.com
Antengene Receives Cde Endorsement to Initiate Pivotal Phase Iii Clinch 3 Study of Atg 022 in Cldn182 Advanced Gastricgej Cancer
dailymail.com